Gland Pharma valuation

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
Price multiples — at each FY-end close
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
44.50×————
4.85×————
7.47×————
93.56×————
Enterprise multiples
7.01×————
26.91×————
35.77×————
Yield
2.2%————
1.1%————
Reference — adjusted share basis
₹3,049.00————
₹68.51₹62.35₹42.40₹46.88₹47.40
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

GLAND₹3,049.00

Gland Pharma Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABAUROPHARMAPPLPHARMASYNGENEWOCKPHARMAASTERDMCOHANCELALPATHLABMcap ₹50,235 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
Multiples — ₹ Crore base
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Price Multiples — at each FY-end close
P/E————44.50
P/B————4.85
P/Sales————7.47
Price to Free Cash Flow————93.56
Enterprise Multiples
EV/Sales————7.01
EV/EBITDA————26.91
EV/EBIT————35.77
Yield
Earnings Yield %————2.25
FCF Yield %————1.07
Reference — adjusted share basis
Price (FY-end close, adj.)————3,049.00
EPS (adj.)47.4046.8842.4062.3568.51
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.